The metabolome 18 years on: a concept comes of age

Metabolomics

Volumn 12, Issue 10, 2016, Pages

  Kell, Douglas B ^a   Oliver, Stephen G ^b,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Functional genomics; Metabolome; Precision medicine; Systems biology

Indexed keywords

ADULT; FUNCTIONAL GENOMICS; METABOLOME; METABOLOMICS; PERSONALIZED MEDICINE; SCIENTIFIC LITERATURE; SYSTEMS BIOLOGY; YOUNG ADULT;

EID: 84985918208     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-016-1108-4     Document Type: Review

References (138)

1. Abate-Pella, D., Freund, D. M., Ma, Y., et al. (2015). Retention projection enables accurate calculation of liquid chromatographic retention times across labs and methods. Journal of Chromatography A, 1412, 43–51.
2. Alexander, J., Gildea, L., Balog, J., et al. (2016) A novel methodology for in vivo endoscopic phenotyping of colorectal cancer based on real-time analysis of the mucosal lipidome: A prospective observational study of the iKnife. Surgical Endoscopy 1-10.
3. Allen, J. K., Davey, H. M., Broadhurst, D., et al. (2003). High-throughput characterisation of yeast mutants for functional genomics using metabolic footprinting. Nature Biotechnology, 21, 692–696.
4. Allen, J., Davey, H. M., Broadhurst, D., et al. (2004). Discrimination of the modes of action of antifungal substances by use of metabolic footprinting. Applied and Environmental Microbiology, 70, 6157–6165.
5. Ashton, P. M., Nair, S., Dallman, T., et al. (2015). MinION nanopore sequencing identifies the position and structure of a bacterial antibiotic resistance island. Nature Biotechnology, 33, 296–300.
6. Athersuch, T. J., & Keun, H. C. (2015). Metabolic profiling in human exposome studies. Mutagenesis, 30(6), 755–762.
7. Ball, P., & Garwin, L. (1992). Science at the atomic scale. Nature, 355, 761–766.
8. Balog, J., Sasi-Szabó, L., Kinross, J., et al. (2013). Intraoperative tissue identification using rapid evaporative ionization mass spectrometry. Science Translational Medicine, 5, 194ra93.
9. Begley, P., Francis-McIntyre, S., Dunn, W. B., et al. (2009). Development and performance of a gas chromatography-time-of-flight mass spectrometry analysis for large-scale non-targeted metabolomic studies of human serum. Analytical Chemistry, 81, 7038–7046.
10. Bradbury, J., Genta-Jouve, G., Allwood, J. W., et al. (2015). MUSCLE: Automated multi-objective evolutionary optimization of targeted LC-MS/MS analysis. Bioinformatics, 31, 975–977.
11. Broadhurst, D., & Kell, D. B. (2006). Statistical strategies for avoiding false discoveries in metabolomics and related experiments. Metabolomics, 2, 171–196.
12. Brown, M., Dunn, W. B., Dobson, P., et al. (2009). Mass spectrometry tools and metabolite-specific databases for molecular identification in metabolomics. Analyst, 134, 1322–1332.
13. Bu’lock, J. D. (1961). Intermediary metabolism and antibiotic synthesis. Advances in Applied Microbiology Physiology, 3, 293–333.
14. Bundy, J. G., Davey, M. P., & Viant, M. R. (2009). Environmental metabolomics: A critical review and future perspectives. Metabolomics, 5, 3–21.
15. Carbonell, P., Parutto, P., Herisson, J., et al. (2014). XTMS: Pathway design in an eXTended metabolic space. Nucleic Acids Research, 42, W389–W394.
16. Carbonell, P., Planson, A. G., & Faulon, J. L. (2013). Retrosynthetic design of heterologous pathways. Systems Metabolic Engineering, 985, 149–173.
17. Castrillo, J. I., & Oliver, S. G. (2004). Yeast as a touchstone in post-genomic research: Strategies for integrative analysis in functional genomics. Journal of Biochemistry and Molecular Biology, 37, 93–106.
18. Castrillo, J. I., Zeef, L. A., Hoyle, D. C., et al. (2007). Growth control of the eukaryote cell: a systems biology study in yeast. Journal of Biology, 6, 4.
19. César-Razquin, A., Snijder, B., Frappier-Brinton, T., et al. (2015). A call for systematic research on solute carriers. Cell, 162, 478–487.
20. Chance, B., & Williams, G. R. (1955). Respiratory enzymes in oxidative phosphorylation. III The steady state. Journal of Biological Chemistry, 217, 409–427.
21. Cobb, M. (2015). Life’s greatest secret: The race to crack the genetic code. London: Profile Books.
22. Coles, S. J., Day, N. E., Murray-Rust, P., Rzepa, H. S., & Zhang, Y. (2005). Enhancement of the chemical semantic web through the use of InChI identifiers. Organic & Biomolecular Chemistry, 3, 1832–1834.
23. Cooks, R. G., Ouyang, Z., Takats, Z., & Wiseman, J. M. (2006). Ambient mass spectrometry. Science, 311, 1566–1570.
24. Cornish-Bowden, A., & Cárdenas, M. L. (2001). Silent genes given voice. Nature, 409, 571–572.
25. Currin, A., Swainston, N., Day, P. J., & Kell, D. B. (2015). Synthetic biology for the directed evolution of protein biocatalysts: navigating sequence space intelligently. Chemical Society Reviews, 44, 1172–1239.
26. Dalgliesh, C. E., Horning, E. C., Horning, M. G., Knox, K. L., & Yarger, K. (1966). A gas-liquid-chromatographic procedure for separating a wide range of metabolites occuring in urine or tissue extracts. Biochemical Journal, 101, 792–810.
27. Dettmer, K., Aronov, P. A., & Hammock, B. D. (2007). Mass spectrometry-based metabolomics. Mass Spectrometry Reviews, 26, 51–78.
28. Dikicioglu, D., Pir, P., & Oliver, S. G. (2013). Predicting complex phenotype-genotype interactions to enable yeast engineering: Saccharomyces cerevisiae as a model organism and a cell factory. Biotechnology Journal, 8, 1017–1034.
29. Dobson, P. D., & Kell, D. B. (2008). Carrier-mediated cellular uptake of pharmaceutical drugs: An exception or the rule? Nature Reviews Drug Discovery, 7, 205–220.
30. Dobson, P., Lanthaler, K., Oliver, S. G., & Kell, D. B. (2009a). Implications of the dominant role of cellular transporters in drug uptake. Current Topics in Medicinal Chemistry, 9, 163–184.
31. Dobson, P. D., Patel, Y., & Kell, D. B. (2009b). “Metabolite-likeness” as a criterion in the design and selection of pharmaceutical drug libraries. Drug Discovery Today, 14, 31–40.
32. Dunn, W. B., Broadhurst, D., Begley, P., et al. (2011). TheHusermet consortium,procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nature Protocols, 6, 1060–1083.
33. Dunn, W. B., Broadhurst, D. I., Sasalu, D., et al. (2007). Serum metabolomics reveals many novel metabolic markers of heart failure, including pseudouridine and 2-oxoglutarate. Metabolomics, 3, 413–426.
34. Dunn, W. B., Erban, A., Weber, R. J. M., et al. (2013). Mass Appeal: Metabolite identification in mass spectrometry-focused untargeted metabolomics. Metabolomics, 9, S44–S66.
35. Dunn, W. B., Lin, W., Broadhurst, D., et al. (2015). Molecular phenotyping of a UK population: Defining the human serum metabolome. Metabolomics, 11, 9–26.
36. Ellis, D. I., Muhamadali, H., Haughey, S. A., et al. (2015). Point-and-shoot: rapid quantitative detection methods for on-site food fraud analysis—moving out of the laboratory and into the food supply chain. Anal Meth, 7, 9401–9414.
37. Fell, D. A. (1992). Metabolic Control Analysis—a survey of its theoretical and experimental development. Biochemical Journal, 286, 313–330.
38. Fell, D. A. (1996). Understanding the control of metabolism. London: Portland Press.
39. Fiehn, O. (2002). Metabolomics: The link between genotypes and phenotypes. Plant Molecular Biology, 48, 155–171.
40. Fiehn, O., Kopka, J., Dormann, P., Altmann, T., Trethewey, R. N., & Willmitzer, L. (2000). Metabolite profiling for plant functional genomics. Nature Biotechnology, 18, 1157–1161.
41. Goffeau, A., Barrell, B. G., Bussey, H., et al. (1996). Life with 6000 genes. Science, 274, 546–567.
42. Goodacre, R., Broadhurst, D., Smilde, A., et al. (2007). Proposed minimum reporting standards for data analysis in metabolomics. Metabolomics, 3, 231–241.
43. Goodacre, R., Timmins, É. M., Burton, R., et al. (1998). Rapid identification of urinary tract infection bacteria using hyperspectral whole-organism fingerprinting and artificial neural networks. Microbiology, 144, 1157–1170.
44. Goodacre, R., Vaidyanathan, S., Bianchi, G., & Kell, D. B. (2002). Metabolic profiling using direct infusion electrospray ionisation mass spectrometry for the characterisation of olive oils. Analyst, 127, 1457–1462.
45. Goodacre, R., Vaidyanathan, S., Dunn, W. B. (2004). Metabolomics by numbers: acquiring and understanding global metabolite data. Trends in Biotechnology, 22, 245–252.
46. Grant, B. R., Greenaway, W., & Whatley, F. R. (1988). Metabolic changes during development of Phytophthora palmivora examined by Gas-Chromatography Mass-Spectrometry. Journal of General Microbiology, 134, 1901–1911.
47. Grapov, D., Wanichthanarak, K., & Fiehn, O. (2015). MetaMapR: Pathway independent metabolomic network analysis incorporating unknowns. Bioinformatics, 31, 2757–2760.
48. Greenaway, W., May, J., Scaysbrook, T., & Whatley, F. R. (1991). Identification by gas chromatography-mass spectrometry of 150 compounds in propolis. Zeitschrift für Naturforschung C, 46, 111–121.
49. Griffin, J. L. (2006). The Cinderella story of metabolic profiling: does metabolomics get to go to the functional genomics ball? Philosophical Transactions of the Royal Society of London B, 361, 147–161.
50. Haug, K., Salek, R. M., Conesa, P., et al. (2013). MetaboLights-an open-access general-purpose repository for metabolomics studies and associated meta-data. Nucleic Acids Research, 41, D781–D786.
51. Hediger, M. A., Romero, M. F., Peng, J. B., et al. (2004). The ABCs of solute carriers: Physiological, pathological and therapeutic implications of human membrane transport proteins. Pflügers Archiv, 447, 465–468.
52. Heinrich, R., & Rapoport, T. A. (1974). A linear steady-state treatment of enzymatic chains. General properties, control and effector strength. European Journal of Biochemistry, 42, 89–95.
53. Heinrich, R., & Schuster, S. (1996). The regulation of cellular systems. New York: Chapman & Hall.
54. Heller, S., McNaught, A., Stein, S., et al. (2013). InChI—the worldwide chemical structure identifier standard. Journal of Cheminformatics, 5, 7.
55. Herrgård, M. J., Swainston, N., Dobson, P., et al. (2008). A consensus yeast metabolic network obtained from a community approach to systems biology. Nature Biotechnology, 26, 1155–1160.
56. Hirschman, J. E., Balakrishnan, R., Christie, K. R., et al. (2006). Genome Snapshot: A new resource at the Saccharomyces Genome Database (SGD) presenting an overview of the Saccharomyces cerevisiae genome. Nucleic Acids Research, 34, D442–D445.
57. Honda, K., & Littman, D. R. (2016). The microbiota in adaptive immune homeostasis and disease. Nature, 535, 75–84.
58. Horning, E. C., & Horning, M. G. (1971). Metabolic profiles: Gas-phase methods for analysis of metabolites. Clinical Chemistry, 17, 802–809.
59. Ioannidis, J. P. A. (2005). Why most published research findings are false. PLoS Medicine, 2, e124.
60. Jeffryes, J. G., Colastani, R. L., Elbadawi-Sidhu, M., et al. (2015). MINEs: Open access databases of computationally predicted enzyme promiscuity products for untargeted metabolomics. Journal of Cheminformatics, 7, 44.
61. Jenkins, H., Hardy, N., Beckmann, M., et al. (2004). A proposed framework for the description of plant metabolomics experiments and their results. Nature Biotechnology, 22, 1601–1606.
62. Jewison, T., Knox, C., Neveu, V., et al. (2012). YMDB: The yeast metabolome database. Nucleic Acids Research, 40, D815–D820.
63. Judson, H. F. (1979). The eighth day of creation: Makers of the revolution in biology. New York: Touchstone Books.
64. Kacser, H., & Burns, J. A. (1973). The control of flux in Davies. In D. D. Davies (Ed.), Rate control of biological processes. symposium of the society for experimental biology (pp. 65–104). Cambridge: Cambridge University Press.
65. Kacser, H., & Burns, J. A. (1981). The molecular basis of dominance. Genetics, 97, 639–666.
66. Kaderbhai, N. N., Broadhurst, D. I., Ellis, D. I., et al. (2003). Functional genomics via metabolic footprinting: Monitoring metabolite secretion by Escherichia coli tryptophan metabolism mutants using FT-IR and direct injection electrospray mass spectrometry. Comparative Functional Genomics, 4, 376–391.
67. Kell, D. B. (2004). Metabolomics and systems biology: making sense of the soup. Current Option in Microbiology, 7, 296–307.
68. Kell, D. B. (2006). Systems biology, metabolic modelling and metabolomics in drug discovery and development. Drug Disc Today, 11, 1085–1092.
69. Kell, D. B. (2013). Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening, and knowledge of transporters: Where drug discovery went wrong and how to fix it. FEBS Journal, 280, 5957–5980.
70. Kell, D. B. (2015a). The transporter-mediated cellular uptake of pharmaceutical drugs is based on their metabolite-likeness and not on their bulk biophysical properties: Towards a systems pharmacology. Perspectives on Science, 6, 66–83.
71. Kell, D. B. (2015b). What would be the observable consequences if phospholipid bilayer diffusion of drugs into cells is negligible? Trends in Pharmacological Sciences, 36, 15–21.
72. Kell, D.B. (2016) How drugs pass through biological cell membranes—a paradigm shift in our understanding? Beilstein Magazine 2, http://www.beilstein-institut.de/download/628/09_kell.pdf.
73. Kell, D. B., Brown, M., Davey, H. M., et al. (2005). Metabolic footprinting and Systems Biology: The medium is the message. Nature Reviews Microbiology, 3, 557–565.
74. Kell, D. B., Dobson, P. D., Bilsland, E., & Oliver, S. G. (2013). The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: What we (need to) know and how we can do so. Drug Disc Today, 18, 218–239.
75. Kell, D. B., Dobson, P. D., & Oliver, S. G. (2011). Pharmaceutical drug transport: The issues and the implications that it is essentially carrier-mediated only. Drug Disc Today, 16, 704–714.
76. Kell, D. B., & Oliver, S. G. (2004). Here is the evidence, now what is the hypothesis? The complementary roles of inductive and hypothesis-driven science in the post-genomic era. Bioessays, 26, 99–105.
77. Kell, D. B., & Oliver, S. G. (2014). How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion. Frontiers in Pharmacology, 5, 231.
78. Kell, D. B., Potgieter, M., & Pretorius, E. (2015a). Individuality, phenotypic differentiation, dormancy and ‘persistence’ in culturable bacterial systems: Commonalities shared by environmental, laboratory, and clinical microbiology. F1000Research, 4, 179.
79. Kell, D. B., Swainston, N., Pir, P., & Oliver, S. G. (2015b). Membrane transporter engineering in industrial biotechnology and whole-cell biocatalysis. Trends in Biotechnology, 33, 237–246.
80. Kell, D. B., van Dam, K., & Westerhoff, H. V. (1989). Control analysis of microbial growth and productivity. Symp. Soc. Gen. Microbiol., 44, 61–93.
81. Kell, D. B., & Westerhoff, H. V. (1986). Metabolic control theory: Its role in microbiology and biotechnology. FEMS Microbiology Reviews, 39, 305–320.
82. Kenny, L. C., Broadhurst, D. I., Dunn, W., et al. (2010). Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. Hypertension, 56, 741–749.
83. Kenny, L. C., Dunn, W. B., Ellis, D. I., et al. (2005). Novel biomarkers for pre-eclampsia detected using metabolomics and machine learning. Metabolomics, 1, 227–234. doi:10.1007/s11306-005-0003-1.
84. Kilianski, A., Haas, J. L., Corriveau, E. J., et al. (2015). Bacterial and viral identification and differentiation by amplicon sequencing on the MinION nanopore sequencer. Gigascience, 4, 12.
85. Kind, T., & Fiehn, O. (2007). Seven golden rules for heuristic filtering of molecular formulas obtained by accurate mass spectrometry. BMC Bioinformatics, 8, 105.
86. King, R. D., Rowland, J., Oliver, S. G., et al. (2009). The automation of science. Science, 324, 85–89.
87. King, R. D., Whelan, K. E., Jones, F. M., et al. (2004). Functional genomic hypothesis generation and experimentation by a robot scientist. Nature, 427, 247–252.
88. Koza, J. R. (2010). Human-competitive results produced by genetic programming. Genetic Programming and Evolvable Machines, 11, 251–284.
89. Lanthaler, K., Bilsland, E., Dobson, P., et al. (2011). Genome-wide assessment of the carriers involved in the cellular uptake of drugs: A model system in yeast. BMC Biology, 9, 70.
90. Lewis, K., Epstein, S., D’Onofrio, A., & Ling, L. L. (2010). Uncultured microorganisms as a source of secondary metabolites. The Journal of Antibiotics (Tokyo), 63, 468–476.
91. Lewis, M.R., Pearce, J.T., Spagou, K., et al. (2016) Development and Application of UPLC-ToF MS for Precision Large Scale Urinary Metabolic Phenotyping. Analytical Chemistry. doi:10.1021/acs.analchem.6b01481.
92. Link, H., Fuhrer, T., Gerosa, L., Zamboni, N., & Sauer, U. (2015). Real-time metabolome profiling of the metabolic switch between starvation and growth. Nature Methods, 12, 1091–1097.
93. Makarov, A., Denisov, E., Kholomeev, A., et al. (2006). Performance evaluation of a hybrid linear ion trap/orbitrap mass spectrometer. Analytical Chemistry, 78, 2113–2120.
94. Mendes, P., Oliver, S. G., & Kell, D. B. (2015). Fitting transporter activities to cellular drug concentrations and fluxes: Why the bumblebee can fly. Trends in Pharmacological Sciences, 36, 710–723.
95. Meuzelaar, H. L. C., Haverkamp, J., & Hileman, F. D. (1982). Pyrolysis mass spectrometry of recent and fossil biomaterials. Amsterdam: Elsevier.
96. Mnih, V., Kavukcuoglu, K., Silver, D., et al. (2015). Human-level control through deep reinforcement learning. Nature, 518, 529–533.
97. Nielsen, J., & Keasling, J. D. (2016). Engineering cellular metabolism. Cell, 164, 1185–1197.
98. O’Hagan, S., Dunn, W. B., Brown, M., Knowles, J. D., & Kell, D. B. (2005). Closed-loop, multiobjective optimisation of analytical instrumentation: Gas-chromatography-time-of-flight mass spectrometry of the metabolomes of human serum and of yeast fermentations. Analytical Chemistry, 77, 290–303.
99. O’Hagan, S., & Kell, D. B. (2015a). The apparent permeabilities of Caco-2 cells to marketed drugs: Magnitude, and independence from both biophysical properties and endogenite similarities. PeerJ, 3, e1405.
100. O’Hagan, S., & Kell, D. B. (2015b). Understanding the foundations of the structural similarities between marketed drugs and endogenous human metabolites. Frontiers in Pharmacology, 6, 105.
101. O’Hagan, S. and Kell, D.B. (2016) MetMaxStruct: A Tversky-similarity-based strategy for analysing the (sub)structural similarities of drugs and endogenous metabolites. Frontiers in Pharmacology, in press.
102. O’Hagan, S., Swainston, N., Handl, J., & Kell, D. B. (2015). A ‘rule of 0.5’ for the metabolite-likeness of approved pharmaceutical drugs. Metabolomics, 11, 323–339.
103. Oliver, S. G. (1996). From DNA sequence to biological function. Nature, 379, 597–600.
104. Oliver, S. G. (2000). Guilt-by-association goes global. Nature, 403, 601–603.
105. Oliver, S. G., Winson, M. K., Kell, D. B., & Baganz, F. (1998). Systematic functional analysis of the yeast genome. Trends in Biotechnology, 16, 373–378.
106. Oliver, S. G., Vanderaart, Q. J. M., Agostonicarbone, M. L., et al. (1992). The complete DNA sequence of yeast chromosome III. Nature, 357, 38–46.
107. Palsson, B. Ø. (2006). Systems biology: Properties of reconstructed networks. Cambridge: Cambridge University Press.
108. Potgieter, M., Bester, J., Kell, D. B., & Pretorius, E. (2015). The dormant blood microbiome in chronic, inflammatory diseases. FEMS Microbiology Reviews, 39, 567–591.
109. Quanbeck, S. M., Brachova, L., Campbell, A. A., et al. (2012). Metabolomics as a hypothesis-generating functional genomics tool for the annotation of arabidopsis thaliana genes of “unknown function”. Frontiers in Plant Science, 3, 15.
110. Raamsdonk, L. M., Teusink, B., Broadhurst, D., et al. (2001). A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nature Biotechnology, 19, 45–50.
111. Rappaport, S. M., Barupal, D. K., Wishart, D., Vineis, P., & Scalbert, A. (2014). The blood exposome and its role in discovering causes of disease. Environmental Health Perspectives, 122, 769–774.
112. Rattray, N. J. W., Hamrang, Z., Trivedi, D. K., et al. (2014). Taking your breath away: metabolomics breathes life into personalized medicine. Trends in Biotechnology, 32, 538–548.
113. Rocca-Serra, P., Salek, R. M., Arita, M., et al. (2016). Data standards can boost metabolomics research, and if there is a will, there is a way. Metabolomics, 12, 14.
114. Salek, R. M., Neumann, S., Schober, D., et al. (2015). COordination of Standards in MetabOlomicS (COSMOS): Facilitating integrated metabolomics data access. Metabolomics, 11, 1587–1597.
115. Salek, R. M., Steinbeck, C., Viant, M. R., et al. (2013). The role of reporting standards for metabolite annotation and identification in metabolomic studies. GigaScience, 2, 13.
116. Sansone, S. A., Fan, T., Goodacre, R., et al. (2007). The metabolomics standards initiative. Nature Biotechnology, 25, 846–848.
117. Silver, D., Huang, A., Maddison, C. J., et al. (2016). Mastering the game of Go with deep neural networks and tree search. Nature, 529, 484–489.
118. Skogerson, K., Wohlgemuth, G., Barupal, D. K., & Fiehn, O. (2011). The volatile compound binbase mass spectral database. BMC Bioinformatics, 12, 321.
119. Spjuth, O., Berg, A., Adams, S., & Willighagen, E. L. (2013). Applications of the InChI in cheminformatics with the CDK and Bioclipse. Journal of Cheminformatics, 5, 14.
120. Stajich, J. E., Dietrich, F. S., & Roy, S. W. (2007). Comparative genomic analysis of fungal genomes reveals intron-rich ancestors. Genome Biology, 8, R223.
121. Swainston, N., Smallbone, K., Hefzi, H., et al. (2016). Recon 2.2: From reconstruction to model of human metabolism. Metabolomics, 12, 109.
122. Teusink, B., Baganz, F., Westerhoff, H. V., & Oliver, S. G. (1998). Metabolic Control Analysis as a tool in the elucidation of the function of novel genes. In M. F. Tuite & A. J. P. Brown (Eds.), Methods in microbiology: Yeast gene analysis (pp. 297–336). London: Academic Press.
123. Thiele, I., Swainston, N., Fleming, R. M. T., et al. (2013). A community-driven global reconstruction of human metabolism. Nature Biotechnology, 31, 419–425.
124. Vaidyanathan, S., Rowland, J. J., Kell, D. B., & Goodacre, R. (2001). Rapid discrimination of aerobic endospore-forming bacteria via electrospray ionization mass spectrometry of whole cell suspensions. Analytical Chemistry, 73, 4134–4144.
125. Walter, R. P., Morris, J. G., & Kell, D. B. (1987). The roles of osmotic stress and water activity in the inhibition of the growth, glycolysis and glucose phosphotransferase system of Clostridium pasteurianum. Journal of General Microbiology, 133, 259–266.
126. Wang, Z., Klipfell, E., Bennett, B. J., et al. (2011). Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature, 472, 57–63.
127. Weber, R. J., Southam, A. D., Sommer, U., & Viant, M. R. (2011). Characterization of isotopic abundance measurements in high resolution FT-ICR and Orbitrap mass spectra for improved confidence of metabolite identification. Analytical Chemistry, 83, 3737–3743.
128. Weininger, D. (1988). SMILES, a chemical language and information system.1. Introduction to methodology and encoding rules. Journal of Chemical Information and Computer Sciences, 28, 31–36.
129. Westerhoff, H. V., Hellingwerf, K. J., & van Dam, K. (1983). Thermodynamic efficiency of microbial growth is low but optimal for maximal growth rate. Proceedings of the National Academy of Sciences of the United States of America, 80, 305–309.
130. Wikoff, W. R., Anfora, A. T., Liu, J., et al. (2009). Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proceedings of the National Academy of Sciences of the United States of America, 10, 3698–3703.
131. Wilkins, M. R., Pasquali, C., Appel, R. D., et al. (1996). From proteins to proteomes: Large scale protein identification by two-dimensional electrophoresis and amino acid analysis. Biotechnology, 14, 61–65.
132. Williams, R. J. (1956). Biochemical Individuality. New York: John Wiley.
133. Williams, K., Bilsland, E., Sparkes, A., et al. (2015). Cheaper faster drug development validated by the repositioning of drugs against neglected tropical diseases. Journal of the Royal Society, Interface, 12, 20141289.
134. Winter, G. E., Radic, B., Mayor-Ruiz, C., et al. (2014). The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity. Nature Chemical Biology, 10, 768–773.
135. Wishart, D. S., Jewison, T., Guo, A. C., et al. (2013). HMDB 3.0—The Human Metabolome Database in 2013. Nucleic Acids Research, 41, D801–D807.
136. 13C-based metabolic flux analysis. Nature Protocols, 4, 878–892.
137. Zelena, E., Dunn, W. B., Broadhurst, D., et al. (2009). Development of a robust and repeatable UPLC-MS method for the long-term metabolomic study of human serum. Analytical Chemistry, 81, 1357–1364.
138. Zhu, Z. J., Schultz, A. W., Wang, J., et al. (2013). Liquid chromatography quadrupole time-of-flight mass spectrometry characterization of metabolites guided by the METLIN database. Nature Protocols, 8, 451–460.